echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer pneumococcal 20-valent conjugate vaccine approved by the U.S. FDA

    Pfizer pneumococcal 20-valent conjugate vaccine approved by the U.S. FDA

    • Last Update: 2021-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pfizer announced today that the U.
    S.
    FDA has approved Prevnar 20 (pneumococcal 20-valent conjugate vaccine) for use in adults 18 years and older to prevent invasive diseases and pneumonia caused by the 20 pneumococcal serotypes in the vaccine
    .

    The press release stated that this is the first approved vaccine against 20 pneumococcal serotypes that cause most aggressive diseases and pneumonia, including 7 serotypes that cause 40% of pneumococcal disease cases and deaths in the United States
    .

    Pfizer's clinical programs in adults include phase 1 and phase 2 clinical trials, as well as 3 phase 3 clinical trials describing vaccine safety and evaluating immunogenicity
    .


    More than 6000 adult subjects 18 years and older participated in three phase 3 trials, including adults 65 years and older, unvaccinated adults, and adults who had previously been vaccinated against pneumococcal vaccine


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.